Drug reference
haemophilus influenzae type b vaccine
conjugated bacterial polysaccharide vaccine · vaccine
conjugated bacterial polysaccharide vaccinevaccine
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
The Haemophilus influenzae type b (Hib) vaccine is a polysaccharide-protein conjugate designed to confer immunity by inducing antibodies to the capsular polysaccharide polyribosylribitol phosphate (PRP).
Indications
prevention of life-threatening childhood bacterial diseases caused by Haemophilus influenzae, including meningitis, bacteremia with sepsis, epiglottitis, buccal, preseptal, and orbital cellulitisProtection of infants and children against H. influenzae meningitisProtection of infants and children against H. influenzae pneumonia
Dosing
- Pediatric
- Infants 2–6 months: 3 doses (0.5 ml i.m.) at 8-week gaps. 7–11 months: 2 doses. Older than 1 year: only 1 dose.
Pharmacokinetics
Bioavailability
Good antibody response and protection obtained in >90% recipients
Related guidelines
Other conjugated bacterial polysaccharide vaccine drugs
Ask House about haemophilus influenzae type b vaccine
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10